基于Meta分析预测肺癌胸部放疗后放射性肺炎的风险评分
本研究基于Meta分析构建并验证了预测肺癌患者胸部放疗后放射性肺炎(RP)的风险评分,评分包含7个变量,总分107分,在亚洲校准队列(n=218)中AUC为0.831,以53.5分为最佳风险分层截断值,并在两个外部验证队列(n=69和n=81)中显示出稳健的区分能力,高风险组RP相对风险显著升高。
要点
- 风险评分包含7个变量:吸烟、化疗、肿瘤位置、肺部合并症、RAS抑制剂使用、V5和V20,总分107分。
- 校准队列AUC为0.831,最佳截断值53.5分,外部验证AUC分别为0.881和0.845。
核心结论
- 基于Meta分析构建的RP风险评分在亚洲队列中独立验证,可提供可靠的风险分层,有助于个体化管理和优化资源分配。
研究设计与样本
- 线性预测因子首先从Meta分析中推导,将定义一致且统计学显著的风险因素的合并OR值转换为β系数并线性变换构建初始评分项。
- 使用独立亚洲校准队列(队列1,n=218)估计模型截距并通过ROC分析确定最佳风险分层截断值。
- 在两个独立亚洲外部验证队列(队列2,n=69;队列3,n=81)中评估区分能力和临床适用性。
- 主要终点为≥2级RP(NCI CTCAE v5.0)。
主要发现
- 最终评分包含7个变量:吸烟、化疗、肿瘤位置、肺部合并症、RAS抑制剂使用、V5和V20,总分107分。
- 校准队列AUC为0.831(95%CI 0.768-0.894),最佳截断值为53.5分。
- 外部验证队列AUC分别为0.881(95%CI 0.799-0.962)和0.845(95%CI 0.749-0.942)。
- 在截断值下,三个队列的阳性似然比分别为3.097、2.934和3.492,阴性似然比分别为0.224、0.159和0.212。
关键数值与推荐
- 风险评分总分107分,最佳风险分层截断值为53.5分。
- 评分变量包括吸烟、化疗、肿瘤位置、肺部合并症、RAS抑制剂使用、V5和V20。
- 主要终点为≥2级RP(NCI CTCAE v5.0)。
临床怎么用
- 该评分系统已制成网页计算器,便于临床使用。
- 可用于肺癌胸部放疗患者的RP风险分层,辅助个体化管理和资源分配。
局限性
- 验证队列均为亚洲人群,外推至其他人群需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To develop and validate a risk score for predicting radiation pneumonitis (RP) in lung cancer patients following thoracic radiation therapy. METHODS AND MATERIALS: The linear predictor was first derived from a meta-analysis. Risk factors with consistent definitions and statistical significance were identified, and their pooled odds ratios were converted to β-coefficients and then linearly transformed to construct the initial scoring items. An independent Asian calibration cohort (cohort 1, n = 218) was used to estimate the model's intercept and to determine the optimal risk stratification cut-off via receiver operating characteristic analysis. The discrimination capability and clinical applicability of the model were subsequently evaluated in 2 independent Asian external validation cohorts (cohort 2, n = 69; cohort 3, n = 81). The primary endpoint was grade ≥2 RP (National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0). RESULTS: The final score for predicting RP included 7 variables: smoking, chemotherapy, tumor location, pulmonary comorbidities, use of renin-angiotensin system inhibitors, percentage of lung volume receiving ≥5 Gy (V5), and percentage of lung volume receiving ≥20 Gy (V20), with a total possible score of 107. It demonstrated an area under the curve of 0.831 (95% CI, 0.768-0.894) in the calibration cohort, establishing 53.5 points as the optimal cut-off value for risk stratification. Discriminative performance remained robust in external validation, with areas under the curve of 0.881 (95% CI, 0.799-0.962) and 0.845 (95% CI, 0.749-0.942), respectively. At this threshold, positive likelihood ratios (LR+) across the 3 cohorts were 3.097, 2.934, and 3.492, and negative likelihood ratios (LR-) were 0.224, 0.159, and 0.212. The high-risk group showed significantly elevated relative risks for RP (7.270, 5.143, and 5.884; all P < .001). To facilitate clinical use, this scoring system has been made available as a web-based calculator. CONCLUSIONS: We developed a meta-analysis-based risk score for RP and independently validated it in Asian cohorts. This tool provides reliable risk stratification that may aid in personalized management and optimization of resource allocation for this population.
引用
- Yang J, Zhu T, Zhou J, et al. A Meta-Analysis-Based Risk Score for Predicting Radiation Pneumonitis After Thoracic Radiation Therapy for Lung Cancer. Int J Radiat Oncol Biol Phys. 2026. PMID: 42140502. doi:10.1016/j.ijrobp.2026.05.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。